Karpas 299

Manufactured by Thermo Fisher Scientific

Sourced in United States

KARPAS 299 is a laboratory instrument designed for the analysis of various types of samples. It utilizes a proprietary technology to perform measurements and data processing. The core function of KARPAS 299 is to provide accurate and reliable analytical results for scientific research and applications.

Automatically generated - may contain errors

Lab products found in correlation

6 protocols using karpas 299

Establishment of EBV-transformed Lymphoblastoid Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

EBV–transformed lymphoblastoid B-cell lines (LCL) was developed in our laboratory as described previously [18 ]. Three lines of LCLs were established from patients with EBV+DLBCL (LCL-1), EBV-DLBCL (LCL-2), and a healthy subject (LCL-3), respectively. In brief, peripheral blood samples were collected and used to generate LCL. Concentrated supernatant from B95-8 cultures, a EBV-transformed marmoset B-cell line, was added to parallel samples in the presence of cyclosporin A in RPMI 1640/20% FCS.
SU-DHL-4, SU-DHL-6, HBL-1, and OCI-Ly-10 DLBCL cell lines were gifts from Dr. Ronald Levy (Stanford University, Stanford, CA, USA). Raji and Daudi human Burkitt lymphoma (BL), Karpas 299 anaplastic large cell lymphoma (ALCL) and Jurkat T-cell lymphoblastic leukemia cell lines were obtained from the American Type Culture Collection (ATCC).
SU-DHL-4, HBL-1, LCL, Raji, Daudi, Karpas 299, and Jurkat cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) plus 10% heat-inactivated fetal calf serum (FCS; Omega Scientific, Tarzana, CA, USA), 100 U/mL penicillin/streptomycin, and 2 mmol/L L-glutamine, at 37°C in 5% CO₂. SU-DHL-6 cells were cultured in RPMI 1640 medium plus 20% FCS. OCI-Ly-10 cells were cultured in Iscove’s Modified Dulbecco’s Media(IMDM) complete medium plus 20% fresh human plasma (heparinized) instead of FCS.

Quan L., Chen X., Liu A., Zhang Y., Guo X., Yan S, & Liu Y. (2015). PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLoS ONE, 10(9), e0136476.

+ Open protocol

+ Expand

Cell Line Culturing Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

HEK-293, Raji, P-815, KARPAS-299, L540CY, L428, L1236, and HDLM-2 cell lines were cultured under standard conditions in DMEM or RPMI 1640 medium supplemented with: 10% heat-inactivated FCS, 100 U/mL penicillin G, 100 µg/mL streptomycin, and 2 mM L-glutamine (all Invitrogen). HEK-293 cells (catalog number ACC 305), KARPAS-299 cells (catalog number ACC 31), L428 cells (catalog number ACC 197), L1236 cells (catalog number ACC 530), HDLM-2 cells (catalog number ACC 17) were purchased (DSMZ). L540CY, Raji, and P-815, were provided by Dr. Moldenhauer (DKFZ Heidelberg).

Reusch U., Burkhardt C., Fucek I., Le Gall F., Le Gall M., Hoffmann K., Knackmuss S.H., Kiprijanov S., Little M, & Zhukovsky E.A. (2014). A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. mAbs, 6(3), 727-738.

+ Open protocol

+ Expand

Comparative Study of Leukemia and Lymphoma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

THP-1 (Acute Monoblastic/Monocytic Leukemia), OCI-AML3 (Acute Myeloid Leukemia), Karpas299 (ALK-Positive Anaplastic Large Cell Lymphoma), MV4-11 (Acute Monoblastic/Monocytic Leukemia), K562 (Chronic Myelogenous Leukemia) and Lenti-X™293 T (human embryonic kidney cell) cell lines used in this study were purchased from American Type Culture Collection bank and ensured for mycoplasma-free before experiments. THP-1, OCI-AML3, Karpas299, MV4-11 and K562 were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA). Lenti-X™293 T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, USA) supplemented with 10% FBS. Cells lines were maintained in the incubator with 37 ℃ and 5% CO_2. MV4-11 and THP-1 cells stably expressing firefly luciferase (ffLuc) were established by transduction with the lentivirus simultaneously encoding firefly luciferase and puromycin resistance gene, and cultured in a complete medium added with 1ug/mL puromycin (Gibco, USA).

Cheng J., Ge T., Zhu X., Wang J., Zeng Y., Mu W., Cai H., Dai Z., Jin J., Yang Y., Hu G., Mao X., Zhou J., Zhu L, & Huang L. (2023). Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunology, Immunotherapy, 72(7), 2331-2346.

+ Open protocol

+ Expand

Culturing Human Leukemia and NK Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human leukemia cells were obtained from residual samples on a protocol approved by the Institutional Review Board of Stony Brook University. Cord blood cells were also obtained under protocol from donors at Stony Brook University Hospital. Written, informed consent was obtained from all donors. KARPAS-299, HL-60, CCRF-CEM, MOLT4 and NK-92 cell lines were obtained from ATCC (Manassas, VA). NK-92 cells were cultured in filtered NK cell media, defined as alpha-MEM without ribonucleosides and deoxyribonucleosides with 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 12.5% heat-inactivated horse serum, 12.5% heat-inactivated FBS, 1X Pen/Strep, 0.2% inositol, 0.02% folic acid, and 50 uM beta-mercaptoethanol, supplemented with IL-2 (300 IU/mL), unless otherwise specified. KARPAS-299, CCRF-CEM, and MOLT4 cell lines were cultured in RPMI, 10% FBS, 1x Pen/Strep (Gibco, Waltham, MA, USA). HL-60 cells were cultured in IMDM, 10% FBS, 1x Pen/Strep (Gibco, Waltham, MA, USA).

Pinz K.G., Yakaboski E., Jares A., Liu H., Firor A.E., Chen K.H., Wada M., Salman H., Tse W., Hagag N., Lan F., Leung E.L., Jiang X, & Ma Y. (2017). Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget, 8(68), 112783-112796.

+ Open protocol

+ Expand

Culturing Human Immune Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human primary tumor samples were obtained from residual bone-marrow aspirate samples after final diagnosis was made according to compliance protocols. KARPAS 299, CCRF-CEM, Jurkat, MOLT-4, JeKo and NK-92 cell lines were obtained from ATCC (Manassas, VA). NK-92 cells were cultured in NK-92 cell media (defined as alpha-MEM without ribonucleosides and deoxyribonucleosides with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 12.5% heat-inactivated horse serum, 12.5% heat-inactivated FBS, 1 × Pen/Strep, 0.2% inositol, 0.02% folic acid and 50 uM beta-mercaptoethanol) supplemented with IL-2 (300 IU/ml) and fresh media every 2 days to a maintenance cell density of 0.3–1 × 10⁶ cells/ml. NK-92 cells were then maintained for up to 3 months for in vitro and in vivo experiments. KARPAS 299, CCRF-CEM and Jurkat cell lines were cultured in RPMI, 10% FBS, 1 × Pen/Strep (Gibco, Waltham, MA, USA).

Chen K.H., Wada M., Pinz K.G., Liu H., Lin K.W., Jares A., Firor A.E., Shuai X., Salman H., Golightly M., Lan F., Senzel L., Leung E.L., Jiang X, & Ma Y. (2017). Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia, 31(10), 2151-2160.

+ Open protocol

+ Expand

Culturing Primary Tumor Samples and Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human primary tumor samples were obtained from residual samples following a protocol approved by the Institutional Review Board of Stony Brook University. KARPAS 299, CCRF-CEM, Jurkat, and NK-92 cell lines were obtained from ATCC (Manassas, VA). NK-92 cells were cultured in filtered NK-92 cell media (defined as alpha-MEM without ribonucleosides and deoxyribonucleosides with 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 12.5% heat-inactivated horse serum, 12.5% heat-inactivated FBS, 1X Pen/Strep, 0.2% inositol, 0.02% folic acid, and 50 uM beta-mercaptoethanol, supplemented with IL-2 (300 IU/mL), unless otherwise specified. KARPAS 299, CCRF-CEM, and Jurkat cell lines were cultured in RPMI, 10% FBS, 1x Pen/Strep (Gibco, Waltham, MA, USA).

Chen K.H., Wada M., Firor A.E., Pinz K.G., Jares A., Liu H., Salman H., Golightly M., Lan F., Jiang X, & Ma Y. (2016). Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget, 7(35), 56219-56232.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!